Merck & Co Inc - Company Profile
Powered by 
All the data and insights you need on Merck & Co Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Merck & Co Inc Strategy Report
- Understand Merck & Co Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreView up-to-date information on Merck & Co Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4058371A1 | Application | KENNZEICHNUNGSHÜLLE FÜR EIN MEDIKAMENTENFLÄSCHCHEN | B65D25/205; B65D77/0486 | September 21, 2022 |
| EP3083693B1 | Grant | ANTIKÖRPER GEGEN HUNDE-PD-1 | A61K2039/505; A61K2039/55516; A61K39/00; A61K39/3955; A61P37/04; C07K14/70521; C07K16/28; C07K16/2803; C07K16/2818; C07K16/2896; C07K2317/24; C07K2317/34; C07K2317/52; C07K2317/565; C07K2317/76; C07K2317/92; C07K2319/30 | September 21, 2022 |
| CN115066259A | Application | 使用LIV1-ADC和PD-1拮抗剂的组合疗法 | A61K2039/505; A61K2039/507; A61K2039/54; A61K2039/545; A61K2039/55; A61K38/07; A61K39/3955; A61K47/65; A61K47/6803; A61K47/6817; A61K47/6849; A61K47/6855; A61P35/00; C07K16/28; C07K16/2818; C07K16/2827 | September 16, 2022 |
| WO2022192055A1 | Application | REDUCING HIGH MANNOSE GLYCAN PROTEIN EXPRESSION USING GUANOSINE 5'-MONOPHOSPHATE | September 15, 2022 | |
| WO2022192411A1 | Application | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | September 15, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer